Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Quince Therapeutics, Inc.

Quince Therapeutics Presents Data from Patient-Reported Walking Capacity in Children with Ataxia-Telangiectasia at 54th Child Neurology Society Annual Meeting
From Quince Therapeutics, Inc.
Via Business Wire
Tickers QNCX
Quince Therapeutics Announces CPT: Pharmacometrics & Systems Pharmacology Publication of eDSP Population Pharmacokinetic Modeling Study
From Quince Therapeutics, Inc.
Via Business Wire
Tickers QNCX
Quince Therapeutics to Host Virtual Investor Day on October 2, 2025
From Quince Therapeutics, Inc.
Via Business Wire
Tickers QNCX
Quince Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference
From Quince Therapeutics, Inc.
Via Business Wire
Tickers QNCX
Quince Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results
From Quince Therapeutics, Inc.
Via Business Wire
Tickers QNCX
Quince Therapeutics Selects Option Care Health as Specialty Infusion Therapy Provider for Administration of Lead Asset eDSP
From Quince Therapeutics, Inc.
Via Business Wire
Tickers OPCH QNCX
Quince Therapeutics Completes Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia
From Quince Therapeutics, Inc.
Via Business Wire
Tickers QNCX
Quince Therapeutics Appoints Leading Immunologist Dr. Hassan Abolhassani to Scientific Advisory Board
From Quince Therapeutics, Inc.
Via Business Wire
Tickers QNCX
Quince Therapeutics to Participate at A-T Society’s 2025 A-T Clinical Research Conference
From Quince Therapeutics, Inc.
Via Business Wire
Tickers QNCX
Quince Therapeutics Announces Closing of Up to $22 Million Private Placement of Securities
From Quince Therapeutics, Inc.
Via Business Wire
Tickers QNCX
Quince Therapeutics Announces Pricing of Up to $22 Million Private Placement of Securities
From Quince Therapeutics, Inc.
Via Business Wire
Tickers QNCX
Quince Therapeutics Exceeds 75% Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia
From Quince Therapeutics, Inc.
Via Business Wire
Tickers QNCX
Quince Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results
From Quince Therapeutics, Inc.
Via Business Wire
Tickers QNCX
Quince Therapeutics to Present at Citizens Life Sciences Conference
From Quince Therapeutics, Inc.
Via Business Wire
Tickers QNCX
Quince Therapeutics to Present at Jones Healthcare and Technology Innovation Conference
From Quince Therapeutics, Inc.
Via Business Wire
Tickers QNCX
Quince Therapeutics Provides Business Update and Reports Fiscal Year 2024 Financial Results
From Quince Therapeutics, Inc.
Via Business Wire
Tickers QNCX
Quince Therapeutics to Host Investor Webinar Today Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia
From Quince Therapeutics, Inc.
Via Business Wire
Tickers QNCX
Quince Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
From Quince Therapeutics, Inc.
Via Business Wire
Tickers QNCX
Quince Therapeutics Receives Notice of Allowance Covering Innovative Method of Use for Lead Indication Ataxia-Telangiectasia
From Quince Therapeutics, Inc.
Via Business Wire
Tickers QNCX
Quince Therapeutics to Host Investor Webinar on February 7, 2025 Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia
From Quince Therapeutics, Inc.
Via Business Wire
Tickers QNCX
Quince Therapeutics Announces Frontiers in Neurology Publication of Long-Term Safety of EryDex in Pediatric Patients with Ataxia-Telangiectasia
From Quince Therapeutics, Inc.
Via Business Wire
Tickers QNCX
Quince Therapeutics Appoints Renowned Pediatric Neurologist Dr. William Whitehouse to Scientific Advisory Board
From Quince Therapeutics, Inc.
Via Business Wire
Tickers QNCX
Quince Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results
From Quince Therapeutics, Inc.
Via Business Wire
Tickers QNCX
Quince Therapeutics Presents Data from Prior Phase 3 ATTeST Clinical Trial at 2024 International Congress for Ataxia Research
From Quince Therapeutics, Inc.
Via Business Wire
Tickers QNCX
Quince Therapeutics Presents Safety Data from Prior Phase 3 ATTeST Clinical Trial at 53rd Child Neurology Society Annual Meeting
From Quince Therapeutics, Inc.
Via Business Wire
Tickers QNCX
Quince Therapeutics to Participate at Upcoming Investor Conferences
From Quince Therapeutics, Inc.
Via Business Wire
Tickers QNCX
Quince Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
From Quince Therapeutics, Inc.
Via Business Wire
Tickers QNCX
Quince Therapeutics Announces The Lancet Neurology Publication of Phase 3 ATTeST Clinical Trial Data Evaluating EryDex for the Treatment of Ataxia-Telangiectasia (A-T)
From Quince Therapeutics, Inc.
Via Business Wire
Tickers QNCX
Quince Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results
From Quince Therapeutics, Inc.
Via Business Wire
Tickers QNCX
Quince Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of EryDex for the Treatment of Ataxia-Telangiectasia
From Quince Therapeutics, Inc.
Via Business Wire
Tickers QNCX
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.